Risk factors for Staphylococcus aureus bacteremia in patients with rheumatoid arthritis and incidence compared with the general population: protocol for a Danish nationwide observational cohort study

Sabine Sparre Dieperink, Bente Glintborg, Louise Bruun Oestergaard, Mette Nørgaard, Thomas Benfield, Frank Mehnert, Andreas Petersen, Merete Lund Hetland, Sabine Sparre Dieperink, Bente Glintborg, Louise Bruun Oestergaard, Mette Nørgaard, Thomas Benfield, Frank Mehnert, Andreas Petersen, Merete Lund Hetland

Abstract

Introduction: Staphylococcus aureus bacteremia (SAB) is an invasive infection with high mortality and morbidity. Rheumatoid arthritis (RA) is associated with increased risk of infections due to the disease per se and the use of antirheumatic treatments. Few minor studies have previously investigated risk of SAB in patients with RA and indicated increased risk compared with the general population. This nationwide observational study aims to investigate incidence of and risk factors for SAB in adult patients with RA compared with the general population. The effect of disease characteristics (eg, joint erosions, disease duration and activity), different antirheumatic treatments and smoking on SAB risk will be evaluated.

Methods and analysis: All adults (>18 years of age) alive and living in Denmark in 1996-2017 will be identified in The Danish Civil Registration System. Incident patients with RA are identified in the Danish National Patient Registry (DNPR) and the nationwide rheumatology registry, DANBIO, in which information on, for example, antirheumatic treatments, disease characteristics and smoking is collected prospectively in routine care. Information on comorbidities, invasive procedures and prescribed drugs are identified in the DNPR and in The Register of Medicinal Product Statistics. Socioeconomic status is evaluated in national registers on income and education. Incident cases of first-time SAB are identified in The Danish National SAB Database. All registers are linked on an individual level by unique civil registration numbers. Incidence rates and incidence rate ratios will be analysed using Poisson regression models and the impact of possible risk factors will be evaluated.

Ethics and dissemination: All data will be handled in accordance with the General Data Protection Regulation (EU) 2016/679. No ethical approval is necessary in Denmark when handling registry data only. The results will be presented in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology initiative in international peer-reviewed journals and at medical conferences.

Trial registration number: NCT03908086.

Keywords: Staphylococcus aureus; Staphylococcus aureus bacteremia; Antirheumatic agents; Bacteremia; Rheumatoid arthritis.

Conflict of interest statement

Competing interests: TB reports grants from Pfizer, grants from Novo Nordisk Foundation, grants from Simonsen Foundation, grants from GSK, personal fees from Pfizer, and BG reports grants from Pfizer, Biogen and Abbvie, all outside the submitted work.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Petersen A. Staphylococcus aureus bacteraemia cases in Denmark 2017, 2017. Available:
    1. Mejer N, Westh H, Schønheyder HC, et al. . Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis 2012;12:260 10.1186/1471-2334-12-260
    1. Stammler Jaliff B, Dahl-Knudsen J, Petersen A, et al. . Outcome and reinfection after Staphylococcus aureus bacteraemia in individuals with and without HIV-1 infection: a case-control study. BMJ Open 2014;4:e004075 10.1136/bmjopen-2013-004075
    1. Laupland KB, Ross T, Gregson DB. Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008;198:336–43. 10.1086/589717
    1. Smit J, Søgaard M, Schønheyder HC, et al. . Diabetes and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study. Eur J Endocrinol 2016;174:631–9. 10.1530/EJE-16-0023
    1. Bassetti S, Battegay M. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection 2004;32:163–9. 10.1007/s15010-004-3106-0
    1. Jacobsson G, Dashti S, Wahlberg T, et al. . The epidemiology of and risk factors for invasive Staphylococcus aureus infections in Western Sweden. Scand J Infect Dis 2007;39:6–13. 10.1080/00365540600810026
    1. Bhattacharya M, Wozniak DJ, Stoodley P, et al. . Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther 2015;13:1499–516. 10.1586/14787210.2015.1100533
    1. Wertheim HFL, Vos MC, Ott A, et al. . Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. The Lancet 2004;364:703–5. 10.1016/S0140-6736(04)16897-9
    1. Smit J, Kaasch AJ, Søgaard M, et al. . Use of glucocorticoids and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study. Mayo Clin Proc 2016;91:873–80. 10.1016/j.mayocp.2016.04.023
    1. Oestergaard LB, Schmiegelow MD, Bruun NE, et al. . The associations between socioeconomic status and risk of Staphylococcus aureus bacteremia and subsequent endocarditis – a Danish nationwide cohort study. BMC Infect Dis 2017;17:1–9. 10.1186/s12879-017-2691-3
    1. Smit J, López-Cortés LE, Thomsen RW, et al. . Statin use and risk of community-acquired Staphylococcus aureus bacteremia: a population-based case-control study. Mayo Clinic Proceedings 2017;92:1469–78. 10.1016/j.mayocp.2017.07.008
    1. Hughes WT, Kuhn S, Chaudhary S, et al. . Successful Chemoprophylaxis for Pneumocystis carinii Pneumonitis. N Engl J Med 1977;297:1419–26. 10.1056/NEJM197712292972602
    1. Gurwith MJ, Brunton JL, Lank BA, et al. . A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979;66:248–56. 10.1016/0002-9343(79)90539-4
    1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. The Lancet 2010;376:1094–108. 10.1016/S0140-6736(10)60826-4
    1. Bergström U, Jacobsson LTH, Nilsson Jan-Åke, et al. . Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology 2011;50:2005–13. 10.1093/rheumatology/ker258
    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. The Lancet 2016;388:2023–38. 10.1016/S0140-6736(16)30173-8
    1. Cordtz RL, Hawley S, Prieto-Alhambra D, et al. . Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers. Ann Rheum Dis 2018;77:684–9. 10.1136/annrheumdis-2017-212424
    1. Kokkonen H, Stenlund H, Rantapää-Dahlqvist S. Cardiovascular risk factors predate the onset of symptoms of rheumatoid arthritis: a nested case-control study. Arthritis Res Ther 2017;19 10.1186/s13075-017-1351-8
    1. Lindhardsen J, Ahlehoff O, Gislason GH, et al. . The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929–34. 10.1136/ard.2010.143396
    1. Doran MF, Crowson CS, Pond GR, et al. . Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93. 10.1002/art.10524
    1. Widdifield J, Bernatsky S, Paterson JM, et al. . Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res 2013;65:353–61. 10.1002/acr.21812
    1. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971;14:135–7. 10.1002/art.1780140119
    1. Rimoin DL, Wennberg JE, John E. Acute septic arthritis complicating chronic rheumatoid arthritis. JAMA 1966;196:617–13. 10.1001/jama.1966.03100200057018
    1. Weaver A, Troum O, Hooper M, et al. . Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in radius 1. J Rheumatol 2013;40:1275–81. 10.3899/jrheum.121288
    1. Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:290–305. 10.1016/j.berh.2015.05.009
    1. Ramiro S, Sepriano A, Chatzidionysiou K, et al. . Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101–36. 10.1136/annrheumdis-2016-210708
    1. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology 2012;51 Suppl 6(suppl 6):vi37–43. 10.1093/rheumatology/kes283
    1. Winthrop KL, Park S-H, Gul A, et al. . Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1133–8. 10.1136/annrheumdis-2015-207319
    1. Cohen SB, Tanaka Y, Mariette X, et al. . Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62. 10.1136/annrheumdis-2016-210457
    1. Richter A, Listing J, Schneider M, et al. . Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75:1667–73. 10.1136/annrheumdis-2015-207838
    1. Crowson CS, Hoganson DD, Fitz-Gibbon PD, et al. . Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2847–55. 10.1002/art.34530
    1. Dixon WG, Abrahamowicz M, Beauchamp M-E, et al. . Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis 2012;71:1128–33. 10.1136/annrheumdis-2011-200702
    1. Aaltonen KJ, Joensuu JT, Virkki L, et al. . Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol 2015;42:372–8. 10.3899/jrheum.140853
    1. Sams M, Olsen MA, Joshi R, et al. . Staphylococcus aureus sepsis in rheumatoid arthritis. Rheumatol Int 2015;35:1503–10. 10.1007/s00296-015-3239-8
    1. Ibfelt EH, Sørensen J, Jensen DV, et al. . Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish national patient registry. Clin. Epidemiol 2017;9:627–32. 10.2147/CLEP.S141438
    1. Glintborg B, Højgaard P, Lund Hetland M, et al. . Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology 2016;55:659–68. 10.1093/rheumatology/kev392
    1. Jensen D, Hetland ML, Svensson E, et al. . DANBIO national årsrapport 2017, 2017. Available:
    1. von Elm E, Altman DG, Egger M, et al. . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573–8. 10.7326/0003-4819-147-8-200710160-00010
    1. Joost I, Kaasch A, Pausch C, et al. . Staphylococcus aureus bacteremia in patients with rheumatoid arthritis - Data from the prospective INSTINCT cohort. J Infect 2017;74:575–84. 10.1016/j.jinf.2017.03.003
    1. Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 2014;29:541–9. 10.1007/s10654-014-9930-3
    1. Schmidt M, Schmidt SAJ, Sandegaard JL, et al. . The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449–90. 10.2147/CLEP.S91125
    1. Hetland ML, Krogh NS, Hørslev-Petersen K, et al. . Using an electronic platform interactively to improve treatment outcome in patients with rheumatoid arthritis: new developments from the DANBIO registry. Clin Exp Rheumatol 2016;34(5 Suppl 101):S75–S78.
    1. Benfield T, Espersen F, Frimodt-Møller N, et al. . Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect 2007;13:257–63. 10.1111/j.1469-0691.2006.01589.x
    1. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, et al. . Data resource profile: the Danish national prescription registry. Int J Epidemiol 2017;46:798 10.1093/ije/dyw213
    1. Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health 2011;39(7 Suppl):91–4. 10.1177/1403494810394715
    1. Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health 2011;39(7 Suppl):103–5. 10.1177/1403494811405098

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe